1.45 USD
↘ 0.09 (5.84%)AT CLOSE (11:59 AM EDT)
IN8bio, Inc. Common Stock
INABNASDAQ • USD
1.47
↗ 0.02 (1.38%)
POST MARKET (AS OF 07:44 PM EDT)
Post Market
AS OF 07:44 PM EDT
1.47
↗ 0.02 (1.38%)
Market: CLOSED
Open?$1.56
High?$1.57
Low?$1.43
Prev. Close?$1.54
Volume?73.0K
Avg. Volume?70.9K
VWAP?$1.48
Rel. Volume?1.03x
Bid / Ask
Bid?$1.39 × 1.0K
Ask?$1.57 × 100
Spread?$0.18
Midpoint?$1.48
Valuation & Ratios
Market Cap?13.9M
Shares Out?9.8M
Float?7.0M
Float %?70.7%
P/E Ratio?N/A
P/B Ratio?0.61
EPS?-$1.98
Dividend?0.00%
Ex-Dividend?N/A
IN8bio, Inc. Common Stock (INAB) trades at $1.45 per share. The technical outlook is "Strong Sell" and the fundamental picture shows "Neutral". Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.
Technical & fundamental data as of Jun 5, 2026.
News
Profile
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
Employees
18
Market Cap
13.9M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2021-07-30
Address
EMPIRE STATE BUILDING
NEW YORK, NY 10118
Phone: (646) 600-6438
NEW YORK, NY 10118
Phone: (646) 600-6438
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?77
Short Sent.?88
Piotroski F-Score?0/9Weak
Altman Z-Score?-6.91Distress
Confidence?40%Low
Short InterestModerate
Short % of Float?2.33%Low
Short Interest?161.8K
Days to Cover?3.1
Free Float7.0M
Avg Daily Volume52.3K
Settlement Date2026-05-15
Financial Health
Current Ratio?10.50Strong
Quick Ratio?10.50Strong
Cash Ratio?10.17Strong
Debt/Equity?0.01Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?0.61CHEAP▾
Peers100
S&P97
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?0.4CHEAP▾
Peers100
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-83.3%WEAK▾
S&P3
ROA?-72.3%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-14546000
Enterprise Value?$-7846990
Fundamentals ratios updated end of day